 Xeris Pharmaceuticals Inc NASDAQ: XERS is trading significantly higher Monday after the company announced U.S. Food and Drug Administration approval of its New Drug Application for Gvoke for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes two years of age and older. Xeris Pharmaceuticals said it will begin manufacturing scale up immediately and it anticipates its Gvoke Kit will be available in the first quarter of 2022. 